Combination therapy with aTmprss6RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia

Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with  -thalassemia major: a longitudinal study

(2013) S.-R. Pasricha et al.   BLOOD

Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice

(2013) Shuling Guo et al.   JOURNAL OF CLINICAL INVESTIGATION

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine  -thalassemia intermedia

(2012) P. J. Schmidt et al.   BLOOD

Deletion of TMPRSS6 attenuates the phenotype in a mouse model of  -thalassemia

(2012) A. Nai et al.   BLOOD

Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice

(2011) K. E. Finberg et al.   BLOOD

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

(2010) Sara Gardenghi et al.   JOURNAL OF CLINICAL INVESTIGATION

Transferrin therapy ameliorates disease in β-thalassemic mice

(2010) Huihui Li et al.   NATURE MEDICINE

The Serine Protease Matriptase-2 (TMPRSS6) Inhibits Hepcidin Activation by Cleaving Membrane Hemojuvelin

(2008) Laura Silvestri et al.   Cell Metabolism

Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)

(2008) Karin E Finberg et al.   NATURE GENETICS